Fig. 1 · Structure

Documents & Downloads

Ponatinib (AP24534)

Cat. No. A10080 CAS 943319-70-8

BCR-ABL inhibitor

AP24534 (Ponatinib) is a potent multi-kinase and pan-BCR-ABL inhibitor.

In Stock

Publications for Ponatinib

7 publications citing this product

  1. Vidit Gaur, .et al. , ACS Pharmacol Transl Sci, 2025, Jul 7;8(8):2630-2645 PMID: 40810151
  2. Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
  3. Yamamoto Y, .et al. , Anal Biochem, 2019, Feb 13. pii: S0003-2697(18)31083-2 PMID: 30771339
  4. N Naganna, .et al. , EBioMedicine, 2019, Jan 24. pii: S2352-3964(19)30012-X PMID: 30686755
  5. Takuya Hirao, .et al. , Cancer Sci, 2018, Jan; 109(1): 121-131 PMID: 29121435
  6. Brittany M. Duggan, .et al. , Sci Rep, 2017, 7: 1578 PMID: 28484277
  7. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ponatinib (AP24534) binds the inactive DFG-out conformation of ABL T315I; its ethynyl linker accommodates the gatekeeper isoleucine. Recombinant kinase assays show inhibition of native ABL and ABL T315I, alongside several other tyrosine kinases. This broad profile limits its use as a selective probe for a single kinase. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Abl IC50 0.37nM
PDGFRα IC50 1.1nM
VEGFR2 IC50 1.5nM
FGFR1 IC50 2.2nM
c-Src IC50 5.4nM
c-Kit IC50 12.5nM
InsulinReceptor IC50 >1μM
IGF-1R IC50 >1μM
AuroraA IC50 >1μM
CDK2/CyclinE IC50 >1μM

10 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 5.3 μM Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 31668972]
BaF3 IC50 0.0023 μM Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay [PMID: 23600806]
BaF3 IC50 0.006 μM Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay [PMID: 26195136]
BaF3 IC50 0.0073 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay [PMID: 26814890]
BaF3 EC50 0.05 nM Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay [PMID: 27010810]
BaF3 EC50 0.3 nM Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay [PMID: 27010810]
BaF3 IC50 0.9 nM Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay [PMID: 34011155]
BaF3 IC50 1.2 nM Antiproliferative activity against mouse BA/F3 cells expressing wild type ABL after 3 days by MTS assay [PMID: 20513156]
BaF3 IC50 1.9 μM Cytotoxicity against mouse BA/F3 cells after 48 hrs by XTT assay [PMID: 23600806]
BaF3 EC50 10.6 nM Protac activity at Cereblon/BCR/ABL T315I mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in BCR-ABL T315I mutant driven cell viability incubated for 3 days by CCK8 assay [PMID: 32657579]
BaF3 IC50 1219 nM Antiproliferative activity against mouse BA/F3 cells after 3 days by MTS assay [PMID: 20513156]
BaF3 IC50 126.8 nM Antiproliferative activity against mouse BAF3 cells expressing TEL-FGFR4 fusion protein after 72 hrs by CCK8/SRB assay [PMID: 27750146]
BaF3 IC50 136 nM Inhibition of CCDC6/RET V804M mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay [PMID: 27815117]
BaF3 IC50 180.4 nM Inhibition of CCDC6/RET (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay [PMID: 27815117]
BaF3 IC50 39.1 nM Antiproliferative activity against mouse BAF3 cells expressing CCDC6-RET fusion protein after 72 hrs by CCK8/SRB assay [PMID: 27750146]
BaF3 EC50 438 nM Antiproliferative activity against wild type mouse BA/F3 cells incubated for 3 days by CCK8 assay [PMID: 32657579]
BaF3 IC50 53.7 nM Antiproliferative activity against mouse BAF3 cells expressing TEL-KDR fusion protein after 72 hrs by CCK8/SRB assay [PMID: 27750146]
BaF3 IC50 71.5 nM Antiproliferative activity against mouse BAF3 cells expressing CCDC6-RET V840M mutant after 72 hrs by CCK8/SRB assay [PMID: 27750146]
BaF3 IC50 8.8 nM Antiproliferative activity against mouse BA/F3 cells expressing ABL T315I mutant after 3 days by MTS assay [PMID: 20513156]

19 records · Scroll to view more

In Vitro Studies

Ponatinib inhibited proliferation of BCR-ABL-dependent Ba/F3 cells more potently than parental or IL-3-supported cells. It also reduced viability in leukemia models driven by activated FLT3, KIT, FGFR1 or PDGFRα. The less-sensitive control models show that cellular response depends on biological context. [1,2]

Recombinant kinase inhibition profile

Biochemical assay · Recombinant kinase domains and peptide substrates [1]

AP24534 inhibited ABL and ABL T315I and several other tyrosine kinases; activity was weaker against the selected insulin-signaling and serine/threonine kinase comparators.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Native ABL catalytic inhibitionIC50 0.37 nM[1]
ABL T315I catalytic inhibitionIC50 2.0 nM[1]
c-SRC catalytic inhibitionIC50 5.4 nM[1]
LYN catalytic inhibitionIC50 0.24 nM[1]
c-KIT catalytic inhibitionIC50 12.5 nM[1]
VEGFR2 catalytic inhibitionIC50 1.5 nM[1]
FGFR1 catalytic inhibitionIC50 2.2 nM[1]
PDGFRα catalytic inhibitionIC50 1.1 nM[1]
Insulin receptor catalytic inhibitionIC50 >1000 nM[1]
IGF-1R catalytic inhibitionIC50 >1000 nM[1]
Aurora A catalytic inhibitionIC50 >1000 nM[1]
CDK2/Cyclin E catalytic inhibitionIC50 >1000 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Ten inhibitor concentrations; exact series not stated in the main kinase-profile methods.
Method
Cell-free kinase inhibition profiling
Co-treatment
Single-agent ponatinib/AP24534; comparator/control groups are separate.
Reported limits
Incubation duration, vehicle, replicate number and uncertainty estimates are not specified for Table 1 in the read main text.
Methods and source locations

Compound reported in the paper: AP24534 (ponatinib); Compound label in the paper: AP24534

Literature pharmacology of the ponatinib active moiety. Animal doses are those reported by the authors; no free-base/hydrochloride mass conversion or formulation equivalence is established.

Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

Native ABL catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

ABL T315I catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

c-SRC catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

LYN catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

c-KIT catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

VEGFR2 catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

FGFR1 catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

PDGFRα catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

Insulin receptor catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

IGF-1R catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

Aurora A catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

CDK2/Cyclin E catalytic inhibition: Kinase Hotspot radiometric assay; 10 μM [33P]-ATP. — Table 1; Results: Kinase Selectivity Profile of AP24534; Experimental Procedures: Kinase Selectivity Profile of AP24534

BCR-ABL-dependent Ba/F3 proliferation

Cell-based study · Murine Ba/F3 cells expressing native or mutant BCR-ABL, parental cells, and T315I cells with IL-3 [1]

The native and T315I models were more sensitive than parental or IL-3-supported cells. E255V had the highest IC50 among the single mutants in Table 2 (36 nM).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ba/F3 expressing native BCR-ABL proliferationIC50 0.5 nM[1]
Ba/F3 expressing BCR-ABL T315I proliferationIC50 11 nM[1]
Ba/F3 expressing BCR-ABL E255V proliferationIC50 36 nM[1]
Parental Ba/F3 proliferationIC50 1713 nM[1]
Ba/F3 BCR-ABL T315I with IL-3 proliferationIC50 1804 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–625 nM for BCR-ABL-expressing cells; 0–10,000 nM for BCR-ABL-negative cells.
Exposure duration
72 hr
Method
MTS-based viability readout
Co-treatment
Single-agent ponatinib/AP24534; comparator/control groups are separate.
Reported limits
Vehicle and exact dose series for the T315I + IL-3 condition are not specified in the read proliferation methods. Table 2 does not provide dispersion estimates.
Methods and source locations

Compound reported in the paper: AP24534 (ponatinib); Compound label in the paper: AP24534

Literature pharmacology of the ponatinib active moiety. Animal doses are those reported by the authors; no free-base/hydrochloride mass conversion or formulation equivalence is established.

Table 2; Results: AP24534 Inhibits the Growth of Cells Expressing Native or Mutant BCR-ABL; Experimental Procedures: Cell Proliferation Assays

Ba/F3 expressing native BCR-ABL proliferation: 72-hour MTS-based viability assay; mean of three independent experiments performed in quadruplicate. — Table 2; Results: AP24534 Inhibits the Growth of Cells Expressing Native or Mutant BCR-ABL; Experimental Procedures: Cell Proliferation Assays

Ba/F3 expressing BCR-ABL T315I proliferation: 72-hour MTS-based viability assay; mean of three independent experiments performed in quadruplicate. — Table 2; Results: AP24534 Inhibits the Growth of Cells Expressing Native or Mutant BCR-ABL; Experimental Procedures: Cell Proliferation Assays

Ba/F3 expressing BCR-ABL E255V proliferation: 72-hour MTS-based viability assay; mean of three independent experiments performed in quadruplicate. — Table 2; Results: AP24534 Inhibits the Growth of Cells Expressing Native or Mutant BCR-ABL; Experimental Procedures: Cell Proliferation Assays

Parental Ba/F3 proliferation: 72-hour MTS-based viability assay; mean of three independent experiments performed in quadruplicate. — Table 2; Results: AP24534 Inhibits the Growth of Cells Expressing Native or Mutant BCR-ABL; Experimental Procedures: Cell Proliferation Assays

Ba/F3 BCR-ABL T315I with IL-3 proliferation: 72-hour MTS-based viability assay; mean of three independent experiments performed in quadruplicate. — Table 2; Results: AP24534 Inhibits the Growth of Cells Expressing Native or Mutant BCR-ABL; Experimental Procedures: Cell Proliferation Assays

Cellular activity across activated receptor tyrosine kinases

Cell-based study · MV4-11, Kasumi-1, KG1, EOL1 and RS4;11 leukemia cell lines [2]

Ponatinib reduced viability and receptor phosphorylation in four activated-RTK models. RS4;11 viability IC50 was >100 nmol/L; its RTK phosphorylation was not tested in Table 1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MV4-11 (FLT3-ITD) cell viabilityIC50 2 nmol/L[2]
Kasumi-1 (KIT N822K) cell viabilityIC50 8 nmol/L[2]
KG1 (FGFR1OP2-FGFR1) cell viabilityIC50 17 nmol/L[2]
EOL1 (FIP1L1-PDGFRα) cell viabilityIC50 0.5 nmol/L[2]
RS4;11 (native FLT3; no reported activated RTK) cell viabilityIC50 >100 nmol/L[2]
MV4-11 FLT3 receptor phosphorylationIC50 0.3 nmol/L[2]
Kasumi-1 KIT receptor phosphorylationIC50 20 nmol/L[2]
KG1 FGFR1 receptor phosphorylationIC50 3 nmol/L[2]
EOL1 PDGFRα receptor phosphorylationIC50 0.6 nmol/L[2]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing concentrations; individual dose series are shown in Figure 2.
Exposure duration
72 hours for viability; 1 hour for receptor phosphorylation.
Method
MTS viability and immunoblot endpoints
Vehicle
Dimethyl sulfoxide (DMSO)
Co-treatment
Single-agent ponatinib/AP24534; comparator/control groups are separate.
Reported limits
Final DMSO fraction is not stated in the read methods. Table 1 gives IC50 point estimates without dispersion. Authors report no further cell-line authentication.
Methods and source locations

Compound reported in the paper: AP24534 (ponatinib); Compound label in the paper: Ponatinib

Literature pharmacology of the ponatinib active moiety. Animal doses are those reported by the authors; no free-base/hydrochloride mass conversion or formulation equivalence is established.

Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

MV4-11 (FLT3-ITD) cell viability: 72-hour MTS assay; vehicle-normalized; three separate experiments tested in triplicate; curves reported as mean ± SD. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

Kasumi-1 (KIT N822K) cell viability: 72-hour MTS assay; vehicle-normalized; three separate experiments tested in triplicate; curves reported as mean ± SD. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

KG1 (FGFR1OP2-FGFR1) cell viability: 72-hour MTS assay; vehicle-normalized; three separate experiments tested in triplicate; curves reported as mean ± SD. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

EOL1 (FIP1L1-PDGFRα) cell viability: 72-hour MTS assay; vehicle-normalized; three separate experiments tested in triplicate; curves reported as mean ± SD. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

RS4;11 (native FLT3; no reported activated RTK) cell viability: 72-hour MTS assay; vehicle-normalized; three separate experiments tested in triplicate; curves reported as mean ± SD. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

MV4-11 FLT3 receptor phosphorylation: 1-hour phospho-RTK immunoblot; band intensity quantified relative to vehicle; total RTK reprobe; similar results in two independent experiments. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

Kasumi-1 KIT receptor phosphorylation: 1-hour phospho-RTK immunoblot; band intensity quantified relative to vehicle; total RTK reprobe; similar results in two independent experiments. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

KG1 FGFR1 receptor phosphorylation: 1-hour phospho-RTK immunoblot; band intensity quantified relative to vehicle; total RTK reprobe; similar results in two independent experiments. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

EOL1 PDGFRα receptor phosphorylation: 1-hour phospho-RTK immunoblot; band intensity quantified relative to vehicle; total RTK reprobe; similar results in two independent experiments. — Table 1; Figure 2 legend; Materials and Methods: Cell viability assays and Immunoblot analysis; Results: Ponatinib inhibits signaling and proliferation

In Vivo Studies

Oral AP24534/ponatinib inhibited tumor growth in BCR-ABL T315I and FLT3-ITD mouse xenografts. Response depended on dose and model, and lower-dose MV4-11 tumors regrew after treatment ended. These short preclinical studies do not establish a generally safe or effective dose for other models. [1,2]

BCR-ABL T315I xenograft growth inhibition

Animal study · Female nude mice with subcutaneous Ba/F3 BCR-ABL T315I tumors; randomized at approximately 500 mm³ mean tumor volume [1]

AP24534 reduced tumor growth at 10 and 30 mg/kg and caused regression at 50 mg/kg. Tumor-volume curves show mean ± S.E.M.; %T/C is final mean treated/control tumor volume ×100.

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
19 consecutive days
Vehicle
25 mM citrate buffer, pH 2.75
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
10 mg/kg AP24534Vehicle-treated tumor-bearing miceFinal tumor-volume %T/C = 68%; p<0.01 versus vehicle. Maximal body-weight decrease <5%.[1]
30 mg/kg AP24534Vehicle-treated tumor-bearing miceFinal tumor-volume %T/C = 20%; p<0.01 versus vehicle. Maximal body-weight decrease <5%.[1]
50 mg/kg AP24534Vehicle-treated tumor-bearing miceFinal tumor-volume %T/C = 0.9%; p<0.01 versus vehicle; mean tumor volume decreased 96% from treatment start. Maximal body-weight decrease <12%.[1]
10 mg/kg AP24534
Model: Female nude mice with subcutaneous Ba/F3 BCR-ABL T315I tumors
Reported limits: Efficacy-group n and animal age not stated in the read main text; separate PD n=3 is not borrowed.
30 mg/kg AP24534
Model: Female nude mice with subcutaneous Ba/F3 BCR-ABL T315I tumors
Reported limits: Efficacy-group n and animal age not stated in the read main text; separate PD n=3 is not borrowed.
50 mg/kg AP24534
Model: Female nude mice with subcutaneous Ba/F3 BCR-ABL T315I tumors
Reported limits: Efficacy-group n and animal age not stated in the read main text; separate PD n=3 is not borrowed.
Methods and source locations

Compound reported in the paper: AP24534 (ponatinib); Compound label in the paper: AP24534

Literature pharmacology of the ponatinib active moiety. Animal doses are those reported by the authors; no free-base/hydrochloride mass conversion or formulation equivalence is established.

Figure 5B (left) and legend; Results: subcutaneous Ba/F3 BCR-ABL T315I xenograft paragraph; Experimental Procedures: Ba/F3 Tumor Model

10 mg/kg AP24534 · Figure 5B (left) and legend; Results: subcutaneous Ba/F3 BCR-ABL T315I xenograft paragraph; Experimental Procedures: Ba/F3 Tumor Model

30 mg/kg AP24534 · Figure 5B (left) and legend; Results: subcutaneous Ba/F3 BCR-ABL T315I xenograft paragraph; Experimental Procedures: Ba/F3 Tumor Model

50 mg/kg AP24534 · Figure 5B (left) and legend; Results: subcutaneous Ba/F3 BCR-ABL T315I xenograft paragraph; Experimental Procedures: Ba/F3 Tumor Model

FLT3-ITD MV4-11 xenograft response

Animal study · Female CB.17 SCID mice with MV4-11 xenografts; dosing began at approximately 200 mm³ mean tumor volume; n=10/group [2]

Dose-dependent antitumor activity was observed. TGI uses change in treated versus control tumor volume, whereas regression describes decrease from baseline. Lower-dose tumors regrew after treatment; the 10 and 25 mg/kg/day groups had no palpable tumors during follow-up. Tumor-volume curves are reported as mean ± SEM.

Conditions shared by the study groups

Route
Oral
Frequency
Once daily
Treatment course
28 days; 31-day follow-up described for durable response
Vehicle
Aqueous 25 mmol/L citrate buffer, pH 2.75
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
1 mg/kg/day ponatinibVehicle-treated tumor-bearing miceTumor growth inhibition = 46%, P<0.01; TGI calculated over days 0–24.[2]
2.5 mg/kg/day ponatinibVehicle-treated tumor-bearing miceTumor regression during treatment; regrowth is visible after dosing ended.[2]
5 mg/kg/day ponatinibVehicle-treated tumor-bearing miceTumor regression during treatment; regrowth is visible after dosing ended.[2]
10 mg/kg/day ponatinibVehicle-treated tumor-bearing miceComplete and durable regression; no palpable tumors during a 31-day follow-up.[2]
25 mg/kg/day ponatinibVehicle-treated tumor-bearing miceComplete and durable regression; no palpable tumors during a 31-day follow-up.[2]
1 mg/kg/day ponatinib
Model: Female CB.17 SCID mice with MV4-11 flank xenografts; n=10/group
Reported limits: Three vehicle animals were sacrificed before day 28 because of tumor burden; TGI therefore stops at day 24.
2.5 mg/kg/day ponatinib
Model: Female CB.17 SCID mice with MV4-11 flank xenografts; n=10/group
Reported limits: No numeric regression percentage transcribed for this dose. Three vehicle animals were sacrificed before day 28 because of tumor burden.
5 mg/kg/day ponatinib
Model: Female CB.17 SCID mice with MV4-11 flank xenografts; n=10/group
Reported limits: No numeric regression percentage transcribed for this dose. Three vehicle animals were sacrificed before day 28 because of tumor burden.
10 mg/kg/day ponatinib
Model: Female CB.17 SCID mice with MV4-11 flank xenografts; n=10/group
Reported limits: No numeric regression percentage transcribed for this dose. Three vehicle animals were sacrificed before day 28 because of tumor burden.
25 mg/kg/day ponatinib
Model: Female CB.17 SCID mice with MV4-11 flank xenografts; n=10/group
Reported limits: No numeric regression percentage transcribed for this dose. Three vehicle animals were sacrificed before day 28 because of tumor burden.
Methods and source locations

Compound reported in the paper: AP24534 (ponatinib); Compound label in the paper: Ponatinib

Literature pharmacology of the ponatinib active moiety. Animal doses are those reported by the authors; no free-base/hydrochloride mass conversion or formulation equivalence is established.

Figure 4A and legend; Results: In vivo efficacy and pharmacodynamic studies (efficacy paragraph); Materials and Methods: Subcutaneous xenograft model

1 mg/kg/day ponatinib · Figure 4A and legend; Results: In vivo efficacy and pharmacodynamic studies (efficacy paragraph); Materials and Methods: Subcutaneous xenograft model

2.5 mg/kg/day ponatinib · Figure 4A and legend; Results: In vivo efficacy and pharmacodynamic studies (efficacy paragraph); Materials and Methods: Subcutaneous xenograft model

5 mg/kg/day ponatinib · Figure 4A and legend; Results: In vivo efficacy and pharmacodynamic studies (efficacy paragraph); Materials and Methods: Subcutaneous xenograft model

10 mg/kg/day ponatinib · Figure 4A and legend; Results: In vivo efficacy and pharmacodynamic studies (efficacy paragraph); Materials and Methods: Subcutaneous xenograft model

25 mg/kg/day ponatinib · Figure 4A and legend; Results: In vivo efficacy and pharmacodynamic studies (efficacy paragraph); Materials and Methods: Subcutaneous xenograft model

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 943319-70-8
Applications BCR-ABL inhibitor
Formula C29H27F3N6O
Molecular Weight 532.6
Synonyms AP24534
SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 30 mg/mL (56.33 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% CMC Na

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer cell (2009). PMID: 19878872 DOI: 10.1016/j.ccr.2009.09.028 Source material
  2. [2] Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Molecular cancer therapeutics (2011). PMID: 21482694 DOI: 10.1158/1535-7163.mct-10-1044 Source material

Publications

7 publications citing this product

  1. Vidit Gaur, .et al. , ACS Pharmacol Transl Sci, 2025, Jul 7;8(8):2630-2645 PMID: 40810151
  2. Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
  3. Yamamoto Y, .et al. , Anal Biochem, 2019, Feb 13. pii: S0003-2697(18)31083-2 PMID: 30771339
  4. N Naganna, .et al. , EBioMedicine, 2019, Jan 24. pii: S2352-3964(19)30012-X PMID: 30686755
  5. Takuya Hirao, .et al. , Cancer Sci, 2018, Jan; 109(1): 121-131 PMID: 29121435
  6. Brittany M. Duggan, .et al. , Sci Rep, 2017, 7: 1578 PMID: 28484277
  7. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358

Added to your cart

View Cart Checkout
Loading...